确定乌司奴单抗在克罗恩病治疗流程中最有效位置的研究
研究构建马尔可夫模型模拟35岁中重度克罗恩病男性患者,比较乌司奴单抗在标准治疗流程不同位置的效果,以质量调整生命年为主要结局。结果显示乌司奴单抗作为一线生物制剂较其他方案在1年时获得更大质量调整生命年,增量效果为0.016-0.020质量调整生命年,缓解或应答患者增加10%,手术减少2%。
要点
- 乌司奴单抗作为一线生物制剂在1年时获得最大质量调整生命年。
- 与其他方案相比,一线乌司奴单抗使缓解或应答患者增加10%,手术减少2%。
- 模型对转移概率25%的变异不敏感。
核心结论
- 在基于35岁中重度克罗恩病男性患者的模拟中,乌司奴单抗作为一线生物制剂治疗在1年结束时较 later 使用获得更大质量调整生命年。
研究设计与样本
- 构建马尔可夫模型识别包含乌司奴单抗使用1年或以上的克罗恩病最优治疗序列。
- 基础病例为35岁中重度克罗恩病男性,既往未接受生物制剂或免疫调节剂治疗。
- 标准治疗流程定义为初始英夫利西单抗联合硫唑嘌呤,随后阿达木单抗联合硫唑嘌呤、维得利珠单抗,最后手术切除。
- 评估乌司奴单抗在标准治疗前、英夫利西单抗联合硫唑嘌呤后但其余治疗前、英夫利西单抗联合硫唑嘌呤及阿达木单抗后但维得利珠单抗和手术前、或其他生物制剂后但手术前的位置。
- 转移概率和质量调整生命年来自相关试验、观察性研究和时间权衡分析。
主要发现
- 乌司奴单抗作为一线治疗产生最大质量调整生命年,增量效果为0.016-0.020质量调整生命年。
- 与其他方案相比,一线乌司奴单抗在1年时使缓解或应答患者增加10%,手术减少2%。
- 模型对转移概率25%的变异不敏感。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Ustekinumab is a monoclonal antibody against interleukin 12 and interleukin 23 that has been approved by the Food and Drug Administration for treatment of Crohn's disease (CD). We sought to identify the ideal position for ustekinumab in treatment algorithms for CD. METHODS: We constructed a Markov model to identify an optimal treatment sequence for CD that included ustekinumab for 1 year or more. The base case was a 35-year old male with moderate to severe CD who had not previously received biologic or immunomodulator therapy. The standard of care treatment algorithm was defined as initial therapy with infliximab and azathioprine, followed by adalimumab and azathioprine, vedolizumab, and lastly surgical resection. The model assessed positions for ustekinumab before standard of care, ustekinumab after infliximab and azathioprine but before the remaining treatments, after infliximab, azathioprine, and adalimumab but before vedolizumab and surgery, or after the other biologics but before surgery. We derived transition probabilities and quality adjusted life years (QALYs) from relevant trials, observational studies, and time trade-off analyses. Primary analyses consisted of first order Monte Carlo simulation of 100 trials of cohorts of 100,000 individuals. RESULTS: Ustekinumab as first-line therapy yielded the greatest QALYs (incremental effectiveness, 0.016-0.020 QALYs), resulting in 10% more patients in remission or response, and 2% fewer surgeries at 1 year, compared with other algorithms. The model was not sensitive to 25% variation in transition probabilities. CONCLUSIONS: In a simulation based on a 35-year old male patient with moderate to severe CD, we found that ustekinumab as the first-line biologic therapy yields greater QALYs at the end of 1 year than compared with use later in the CD treatment algorithm.
引用
- Scott FI, Hans AK, Gerich ME, et al. Identification of the Most Effective Position for Ustekinumab in Treatment Algorithms for Crohn's Disease. Clin Gastroenterol Hepatol. 2020. PMID: 32801006. doi:10.1016/j.cgh.2020.08.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。